NCT00072072已完成1 期
A Phase I Trial Of A COX-2 Inhibitor (Celecoxib) In Combination With An EGFR Inhibitor (OSI-774) In Metastatic Non-Small Cell Lung Cancer
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 试验地点
- 2
研究概览
简要总结
RATIONALE: Celecoxib may stop the growth of cancer by stopping blood flow to the tumor. Erlotinib and celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Combining celecoxib with erlotinib may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of celecoxib when given together with erlotinib in treating patients with stage IIIB or stage IV non-small cell lung cancer.
详细描述
OBJECTIVES:
Primary
- Determine the biologically active dose of celecoxib administered with erlotinib in patients with stage IIIB or IV non-small cell lung cancer.
- Determine the toxicity profile of this regimen in these patients.
Secondary
- Determine the clinical activity of this regimen, in terms of reduction in tumor burden, in these patients.
- Correlate biological endpoints with cyclooxygenase-2 and epidermal growth factor receptor inhibition in patients treated with this regimen.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 21 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Celecoxib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerLung CancerNCT00104767Jonsson Comprehensive Cancer Center7
已完成
2 期
Celecoxib, Fluorouracil, and Radiation Therapy in Treating Patients With Stage II or Stage III Rectal Cancer That Can Be Removed By SurgeryColorectal CancerNCT00336960Vanderbilt-Ingram Cancer Center24
撤回
1 期
Celecoxib and Erlotinib in Treating Patients With Liver CancerLiver CancerNCT00293436University of California, San Francisco
终止
2 期
Celecoxib in Treating Patients With Relapsed Prostate Cancer Following Radiation Therapy or Radical ProstatectomyProstate CancerNCT00073970UNC Lineberger Comprehensive Cancer Center37
已完成
1 期
Epirubicin and Celecoxib in Treating Patients With Hepatocellular CarcinomaLiver CancerNCT00057980Northwestern University8